Highlights

  • Cochlear Ltd (ASX:COH) closed at AUD 124.86 on 7 August 2026.
  • The share price was -60.22% over the previous year based on the supplied market data.
  • In April 2026, Cochlear reduced FY26 underlying net profit guidance to AUD 290 mn-AUD 330 mn from the previously stated AUD 435 mn-AUD 460 mn range, where it had earlier expected an outcome near the lower end.
  • The next focus is the next result will show whether developed-market implant demand stabilised and how middle east uncertainty affected sales and receivables.

Cochlear Ltd (ASX:COH) ended Friday, 7 August 2026 at AUD 124.86. Over the previous 12 months, the shares moved -60.22%, leaving the stock with a sizeable decline as the market heads deeper into the FY26 reporting period. The share-price move provides one part of the picture; recent company updates add the operating context. For Cochlear Ltd, the next phase will depend on how current trading, earnings delivery and company-specific priorities develop from here.

What Does Cochlear Ltd Do?

Cochlear develops and sells implantable hearing solutions, including cochlear implants and related hearing technologies across global markets.

What Is the Latest Company Update?

In April 2026, Cochlear reduced FY26 underlying net profit guidance to AUD 290 mn-AUD 330 mn from the previously stated AUD 435 mn-AUD 460 mn range, where it had earlier expected an outcome near the lower end. The company cited softer-than-expected cochlear implant trading in developed markets and heightened uncertainty around fourth-quarter sales in the Middle East. Second-half sales growth was revised to 2%-6% in constant currency.

How Has the COH Share Price Performed?

At the 7 August 2026 close, Cochlear Ltd traded at AUD 124.86. The supplied market data shows a one-year move of -60.22%. That decline indicates the stock has been re-rated lower over the period, making upcoming earnings and operational updates particularly relevant to whether sentiment can stabilise.

What Should the Market Watch Next?

The next result will show whether developed-market implant demand stabilised and how Middle East uncertainty affected sales and receivables. Cochlear has also said it is accelerating plans to reshape its cost base while continuing investment to support growth in the adult and seniors segment.

What Are the Key Risks?

Demand softness, reimbursement settings, geopolitical disruption, foreign exchange and product-market execution can affect earnings. Lower production volumes can also pressure gross margins through reduced overhead recovery.

What Is the Outlook for the Shares?

The one-year performance of Cochlear Ltd shows how quickly the market can reassess a company as earnings expectations and operating conditions change. At AUD 124.86, the next major catalyst is likely to come from evidence around the issues highlighted in the latest update rather than the past share-price move alone. For readers following ASX:COH, the most useful signals will be the company’s next financial result, guidance and progress against its stated priorities.